From a tumor biology perspective, these characteristics may stem from the ability of EGFR mutations to amplify downstream signaling cascades, particularly MEK/ERK and PI3K/AKT/mTOR pathways (26, 27). The gene discussed is EGFR; the disease is neoplasm.